Alistair Crombie

One Research has seen significant growth in its patient expense services since its inception with operations across Europe. Current pipelines will see implementation in further territories over the coming months. One Research’s Managing Director Alistair Crombie states: “This demonstrates in the clearest possible terms that our approach is the right one. We undertook two years of R&D to innovate in this field because our clients’ clinical research needs were not being met by available industry providers. We needed operational flexibility, scalability along with viable economies of scale to support our work on a global stage. During the early R&D phase, our team conducted telephone interviews with over 4,000 patients registered with our Volunteer Outreach Programme. We set out to examine the potential barriers to research participation so we could develop an effective solution that met patient needs. Of the 4,000 we interviewed, financial considerations were cited by over 60%.” One Research's approach is holistic, considering all aspects of a patient's journey and is dedicated to making the patient experience as seamless as possible. By reducing workloads for researchers, sponsors/CROs, and enhancing the [...]

The Volunteer Outreach Programme is the result of a long and successful collaboration between Novo Nordisk and One Research. Since 2012, One Research have managed the programme on Novo Nordisk’s behalf, providing the opportunity for thousands of people with diabetes to take part in diabetes clinical trials. To extend research opportunities to diabetes studies run by other organisations, as well as opening up access to research into other conditions, Novo Nordisk is passing ownership of the programme to One Research. This will mean that members of the Volunteer Outreach Programme will be offered a wider opportunity to participate in research relevant to them. It will also provide an invaluable resource for researchers looking for fast and reliable access to volunteers for their studies. The handover will be seamless from the patients’ perspective, with their privacy and data protection rights unaffected. One Research and Novo Nordisk aim to complete the changeover by September 2022.